

## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/Incn20>

### New Synthesis of 5-Carboxy-2'-deoxyuridine and Its Incorporation into Synthetic Oligonucleotides

V. Guerniou<sup>a</sup>, D. Gasparutto<sup>a b</sup>, S. Sauvaigo<sup>a</sup>, A. Favier<sup>a</sup> & J. Cadet<sup>a</sup>

<sup>a</sup> Laboratoire Lésions des Acides Nucléiques, Service de Chimie Inorganique et Biologique, UMR 5046, CEA/DSM/Département de Recherche Fondamentale sur la Matière Condensée, Grenoble, Cedex, France

<sup>b</sup> CEA Grenoble, LAN/SCIB/DREMC, 17, Avenue des Martyrs, F-38054, Grenoble, France  
Published online: 31 Aug 2006.

To cite this article: V. Guerniou, D. Gasparutto, S. Sauvaigo, A. Favier & J. Cadet (2003) New Synthesis of 5-Carboxy-2'-deoxyuridine and Its Incorporation into Synthetic Oligonucleotides, *Nucleosides, Nucleotides and Nucleic Acids*, 22:5-8, 1073-1075, DOI: [10.1081/NCN-120022739](https://doi.org/10.1081/NCN-120022739)

To link to this article: <http://dx.doi.org/10.1081/NCN-120022739>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

## New Synthesis of 5-Carboxy-2'-deoxyuridine and Its Incorporation into Synthetic Oligonucleotides

V. Guerniou, D. Gasparutto,\* S. Sauvaigo, A. Favier, and J. Cadet

Laboratoire Lésions des Acides Nucléiques, Service de Chimie Inorganique  
et Biologique, UMR 5046, CEA/DSM/Département de Recherche  
Fondamentale sur la Matière Condensée,  
Grenoble, Cedex, France


### ABSTRACT

5-Carboxy-2'-deoxyuridine is a methyl oxidation product of thymidine. It can be formed by the menadione-mediated photosensitization of thymidine in aerated aqueous solution. Here in we present a new four-step synthesis of the 5-carboxy-2'-deoxyuridine phosphoramidite building block based on the alkaline hydrolysis of 5-trifluoromethyl-2'-deoxyuridine. The phosphoramidite derivative has been incorporated at defined sites into oligonucleotides using the solid phase synthesis approach.

5-Carboxy-2'-deoxyuridine (CdU) is an oxidized lesion of thymidine that can be formed by menadione-mediated photosensitization of thymidine.<sup>[1]</sup> Therefore, it is important to evaluate the possible biological effects of CdU. For assessing the structural and biological features of this lesion, the use of site-specific modified oligonucleotides appears to be a good approach. Recently, a synthesis has been

\*Correspondence: D. Gasparutto, CEA Grenoble, LAN/SCIB/DREMC, 17, Avenue des Martyrs, F-38054 Grenoble, France; Fax: +33 4 3878 5090; E-mail: dgasparutto@drfmc.ceng.cea.fr.





**Figure 1.** a:  $\text{CF}_3\text{dT}$ ,  $\text{H}_2\text{O}$ ,  $\text{NaOH}$  pH10,  $37^\circ\text{C}$ , 36 h, 90% ; b: HOBT, DCCI,  $\text{Bu}_3\text{N}$ , EtOH anhydre, 15 h, 75% ; c: DMTrCl, DMAP, pyridine, 23 h, 55% ; d: 2-Cyanoethyl-diisopropylchlorophosphoramidite, DIEA,  $\text{CH}_2\text{Cl}_2$ , 3 h under argon atmosphere, quantitative yield.

described.<sup>[2]</sup> Up to now no biological data have been reported in the literature. Here in we report a new method to synthesize 5-Carboxy-2'-deoxyuridine-containing oligonucleotides.

The phosphoramidite derivative of the protected ethyl ester of 5-carboxy-2'-deoxyuridine **5** was prepared from 5-trifluoromethyl-2'-deoxyuridine **1** in 4 steps (Fig. 1). Thus, alkaline hydrolysis of commercially available 5-trifluoromethyl-2'-deoxyuridine **1**<sup>[3]</sup> followed by neutralization with 1M HCl and desalting on a cation exchange Dowex resin gave 5-carboxy-2'-deoxyuridine **2**.<sup>a</sup> The carboxyle function was then esterified by an ethyl group as described.<sup>[2]</sup> The last two steps are standard dimethoxytritylation and phosphitylation.

Using compound **5**, 5-carboxy-2'-deoxyuridine-containing oligonucleotides were synthesized using an automated DNA synthesizer according to the standard  $\beta$ -cyanoethyl phosphoramidite chemistry. After deprotection with 0.1M NaOH at room temperature for 24 h, the oligonucleotides were purified using electrophoresis on denaturing polyacrylamide gel containing 8M urea and then desalted.

The synthetic oligonucleotides were characterized by ESI-MS and MALDI-TOF MS analyses. The enzymatic digestion of the oligonucleotides followed by HPLC-MS/MS analysis has been performed, confirming the presence and the integrity of 5-Carboxy-2'-deoxyuridine into the oligonucleotides.<sup>b</sup>

<sup>a</sup>**2**: ESI-MS (negative mode):  $[\text{M} - \text{H}]^- = 270.9 \pm 0.1$  Da.  $^1\text{H}$  NMR (200 MHz,  $\text{D}_2\text{O}$ )  $\delta$  9.01 (s, 1H, H-6); 6.33 (t, 1H, H-1'); 4.55 (m, 1H, H-3'); 4.17 (m, 1H, H-4'); 3.98 and 3.85 (m, 2H, H-5' and H-5''); 2.62 and 2.48 (m, 2H, H-2' and H-2''). **3**: ESI-MS (positive mode):  $[\text{M} + \text{H}]^+ = 301.1 \pm 0.1$  Da,  $[\text{M} + \text{Na}]^+ = 323.2 \pm 0.1$  Da. **4**: ESI-MS (positive mode):  $[\text{M} + \text{H}]^+ = 624.9 \pm 0.1$  Da,  $[\text{M} + \text{Na}]^+ = 646.9 \pm 0.1$  Da. **5**: ESI-MS (positive mode):  $[\text{M} + \text{H}]^+ = 803.8 \pm 0.1$  Da,  $[\text{M} + \text{Na}]^+ = 825.8 \pm 0.1$  Da.

<sup>b</sup>The following 22-mer-(5-carboxy-2'-deoxyuridine-containing)-oligonucleotide was synthesized:  $5'$  CAC TTC GGA XCG TGA CTG ATC T  $3'$ , with X = CdU. Purity was checked by ESI-MS analysis, MALDI-TOFF MS analysis (calculated MW = 6731.4 Da, found MW (negative mode) = 6731.1 Da) and enzymatic digestion followed by HPLC-MS/MS analysis. All the analyses confirm the purity of the oligonucleotide together as well as the presence and the integrity of CdU **2**.

## REFERENCES

1. Berthod, T.; Cadet, J.; Molko, D. 5-Carboxy-2'-deoxyuridine, a new photooxidation product of thymidine. *J. Photochem. Photobiol.* **1997**, *104*, 97–104.
2. Berthod, T.; Pétillot, Y.; Guy, A.; Cadet, J.; Molko, D. Synthesis of oligonucleotides containing 5-carboxy-2'-deoxyuridine at defined sites. *J. Org. Chem.* **1996**, *61*, 6075–6078.
3. Jones, M.F. The stability of trifluorothymidine: Hydrolysis in buffered aqueous solutions. *J. Pharm. Pharmacol.* **1981**, *33* (5), 274–278.



